Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in kidney transplantation, expected to initiate in late...
First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending final reimbursement...
First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch expected by year-end, pending...
NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC) Marks third NCCN guideline recommendation on ctDNA-MRD testing, following...
Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class...